bot IMUC - ImmunoCellular Therapeutics’ ICT-107 Demonstrates 80 Percent Survival at 2 Years in Phase I Study of Newly Diagnosed Glioblastoma Patients 8:00 AM ET - Business Wire Data to Be Presented at Annual Meeting of American Society of Clinical Oncology.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.